abrocitinib
abrocitinib is listed in the FDA National Drug Code directory with 15 NDC codes, marketed under brand names including Cibinqo, CIBINQO. Available dosage form: tablet, film coated.
Drug Details
- Generic Name
- abrocitinib
- Brand Names
- Cibinqo, CIBINQO
- Application Number
- NDA213871
- Sponsor
- Pfizer Laboratories Div Pfizer Inc
- NDC Codes
- 15
- Dosage Forms
- TABLET, FILM COATED
- Routes
- ORAL
- Active Ingredients
- ABROCITINIB
Indications and Usage
1 INDICATIONS AND USAGE CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. Limitations of Use CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants. CIBINQO is a Janus kinase (JAK) inhibitor indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. ( 1 ) Limitation of Use : CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.